How Isomorphic Labs Makes Money: From AlphaFold to Drugs

Isomorphic Labs, the Alphabet company led by Demis Hassabis, has two disclosed ways to earn money from its AI drug design: collaborations in which drugmakers pay upfront cash, performance-based milestones and royalties, and wholly-owned internal programs it says it is moving towards clinical trials. Until those pay out, investors fund the work.

Our number: the $82.5 million of upfront payments in its Eli Lilly and Novartis deals equals about 1.1% of the $7.7 billion it has raised in three external rounds since March 2025, by our arithmetic. The latest, a $5 billion Series C, was announced on 17 November.

Business Pill · Data Flywheel

An evergreen Business Engineer explainer on data flywheels: when using a product makes it better. It teaches the general idea only and does not discuss Isomorphic Labs.

The key insight: As we read the company’s pages, Isomorphic Labs gives away part of its AlphaFold lineage and keeps the engine that earns money: AlphaFold 3 code and weights are available for academic use, while IsoDDE, which it says more than doubles AlphaFold 3’s accuracy on the hardest benchmark category, is the system behind its partner deals and internal programs.

Where It Came From: AlphaFold

Isomorphic was launched from Alphabet’s DeepMind in 2021 to build on the success of AlphaFold, its 2024 Lilly release says. On 9 October 2024, the Royal Swedish Academy of Sciences awarded half of the Nobel Prize in Chemistry 2024 jointly to Demis Hassabis and John Jumper of Google DeepMind “for protein structure prediction”. The academy says AlphaFold2 has been used by more than two million people from 190 countries.

AlphaFold 3 was developed by Isomorphic Labs and Google DeepMind, the company says, and it is used for drug design with pharmaceutical partners and on internal projects. Since November 2024 its model code and weights have been released for academic use, and Google DeepMind’s AlphaFold Server is free for non-commercial research.

Isomorphic Labs’ announced external funding, cumulative: $0.6 billion (31 March 2025), $2.7 billion afte
Isomorphic Labs’ announced external funding, cumulative: $0.6 billion (31 March 2025), $2.7 billion after the May 2026 Series B and $7.7 billion after the 17 November 2026 Series C, with the Nobel Prize for AlphaFold (9 October 2024) and the Johnson & Johnson collaboration (January 2026) marked. The Lilly and Novartis deals were announced on 7 January 2024. The cumulative total is our arithmetic.

The founder states the mission in plain terms. Announcing the $5 billion round on X on 17 November, Hassabis wrote that it would “accelerate our mission to Solve All Disease” and that the company is “reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines.” (his post)

What Was Posted on X

Demis Hassabis, Isomorphic Labs’ founder and CEO, announced the $5 billion round on X at 12:06 UTC on 17 November 2026, describing the company’s mission as to Solve All Disease and its aim to cut the time and cost of finding new medicines. The explainer quotes it as the founder’s own statement of the mission.

The Engine Behind the Deals

Isomorphic’s own system is the Isomorphic Labs Drug Design Engine (IsoDDE), which it calls a unified computational drug-design system. In its technical report, the company says IsoDDE more than doubles the accuracy of AlphaFold 3 on the hardest category of a protein-ligand generalisation benchmark.

On a test set of antibody-antigen structures, it says IsoDDE outperforms AlphaFold 3 by 2.3x and Boltz-2 by 19.8x in the high-fidelity regime. Its 17 November release says the engine works across multiple therapeutic areas and drug modalities.

Revenue Line One: Pharma Partnerships

Under its January 2024 Lilly deal, Isomorphic receives a $45 million upfront payment and is eligible for up to $1.7 billion in performance-based milestones, plus “tiered royalties of up to low double digits on net sales.” Under the Novartis deal it receives $37.5 million upfront, Novartis funding of select research costs, and up to $1.2 billion in milestones, the releases say.

In February 2025 Novartis added up to three research programs on the same financial terms, and in January 2026 Isomorphic announced a research collaboration with Johnson & Johnson. We broke down the deal terms separately.

Revenue Line Two: Its Own Pipeline

Isomorphic says it advances partnered programs and wholly-owned internal programs. Its 17 November release says it is seeing positive preclinical results in internal programs in oncology and immunology, “setting the stage for clinical entry.”

The same release says proceeds will support its build of AI-first translational and clinical development infrastructure, and Hassabis said the round lets it drive “our first therapeutic programs towards clinical trials”. It gives no date for a first trial. The company has hired Dr. Ben Wolf as Chief Medical Officer, a physician-scientist who previously led clinical trials at Relay Therapeutics.

Who Pays for It Now: Investors

Isomorphic raised $600 million in its first external round in March 2025, $2.1 billion in May 2026 and $5 billion in November 2026, its posts say, with Alphabet investing alongside outside funds. That makes it about 67% of the 2026 AI drug-discovery rounds we tallied, and its rounds sit alongside Waymo’s on Alphabet’s side of the ledger.

The Structural Read

As we read the deal releases, the partnership model pays mostly later: $82.5 million upfront against up to $2.9 billion of performance-based milestones, plus royalties on net sales if drugs reach the market.

As we read the 17 November release, the bigger bet is the internal pipeline: it names oncology and immunology programs and ties the new money to clinical development infrastructure, without giving a date for a first trial.

Sir Demis Hassabis, Founder and CEO of Isomorphic Labs, in its release, 17 November 2026

“Our drug design engine is generating molecules with unprecedented precision and speed.”

Three Implications

FOR DRUGMAKERS In the Lilly and Novartis deals, the partner pays upfront cash, performance-based milestones and royalties for drug discovery work against its targets, the releases show.

FOR INVESTORS By our arithmetic, equity raised is about 93 times the disclosed upfront payments, so the company is funded mainly by investors until milestones, royalties or its own drugs pay out.

RELATED Isomorphic’s pharma deal terms, deal by deal.

The Business Engineer Lens

This story maps onto the Business Engineer framework The Open vs Closed Meta-Framework.

The framework says: “Close the SCARCE layer (keep proprietary) + Open the ABUNDANT layer (commoditize)”

As we read it, AlphaFold 3 for academic use and the free AlphaFold Server are the open layer, and IsoDDE plus the partner and internal programs are the closed one. The framework predates these releases and does not discuss Isomorphic.

Column chart: Isomorphic Labs upfront payments of $82.5 million and up to $2,900 million of milestones in its Lilly and Novartis deals, against $7,700 million of equity raised
Upfront payments ($45 million Lilly, $37.5 million Novartis) and maximum milestone payments ($1.7 billion and $1.2 billion) in Isomorphic Labs’ January 2024 releases, against the $7.7 billion raised in its three external rounds. Royalties are excluded; the totals and the 93x ratio are our arithmetic. Not investment advice.

What Is Not Established

The pages we read do not say how much milestone or royalty money Isomorphic has received, what the Johnson & Johnson collaboration pays, or when its first program will enter a clinical trial. The release for the Series C does not give a valuation.

Isomorphic and its partners were not contacted for this piece.

This Week In The AI Supercycle

AI Lost Its Central Banker, the Lab Oligopoly, and the Future of Open Source

This week’s issue: the Nvidia leadership change, read as the AI build-out losing its central banker: who now finances the GPU landlords, backstops the data centres and sponsors open models, and why two labs are becoming the bank.

Read the full issue →

Business Engineer Framework

The Open vs Closed Meta-Framework

The Business Engineer framework on which layers of a technology stack to keep proprietary and which to open up.

Read the premium analysis →Get 50% off →

The Bottom Line

Isomorphic Labs turns AlphaFold-lineage models into drug candidates for partners, who pay upfront cash, milestones and royalties, and for its own pipeline, which it says is heading towards clinical trials. So far the disclosed upfronts are about 1.1% of the $7.7 billion investors have put in, by our arithmetic.

95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.

A note on sourcing. This explainer rests on Isomorphic Labs’ own pages: its AlphaFold 3 and IsoDDE articles, its interview with its Chief Medical Officer, its January 2024 Lilly and Novartis releases and February 2025 Novartis expansion release (read in full), and its funding posts, plus the Nobel Prize in Chemistry 2024 press release. Model performance figures are the company’s own claims. Totals and ratios are our arithmetic. Not investment advice; for information only.

Sources: Isomorphic Labs, AlphaFold 3 article · Isomorphic Labs, IsoDDE article and technical report · Nobel Prize in Chemistry 2024 press release · Isomorphic Labs Lilly release (PDF), 7 Jan 2024 · Isomorphic Labs Novartis release (PDF), 7 Jan 2024 · Isomorphic Labs, interview with its Chief Medical Officer · Isomorphic Labs Series C release (PDF), 17 Nov 2026

Scroll to Top
FourWeekMBA